We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: CVS Health, General Motors, Enterprise Products, Berkshire Hathaway and PetroChina
Read MoreHide Full Article
For Immediate Release
Chicago, IL – November 8, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include CVS Health (CVS - Free Report) , General Motors (GM - Free Report) , Enterprise Products (EPD - Free Report) , Berkshire Hathaway (BRK.B - Free Report) and PetroChina .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for CVS, GM and Enterprise Products
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including CVS Health, General Motors and Enterprise Products. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
CVS Health’s shares have outperformed the Zacks Drug Stores industry over the last six months losing -17.6% vs. a decline of -21.1%. CVS Health exited the third quarter on a solid note with both earnings and revenues remaining ahead of the expectations.
Slower revenue performance on poor Retail/LTC numbers as well as margin debacle resulted in such a dull bottom line performance by the company in the quarter. Nonetheless, year-over-year growth in the top line was due to strong Pharmacy Services segment that benefited from the upside in the Specialty Pharmacy.
The Zacks analyst is encouraged to note that, despite a soft bottom-line scenario, the company reiterated its earnings outlook for 2017 indicating chances of recovery ahead. The company’s on-going strong 2018 PBM selling season is another upside. Moreover, the Omnicare and Target Pharmacy buyouts are gradually driving enterprise value at CVS Health.
Shares of General Motors have outperformed the Zacks Domestic Automotive industry over the last six months, increasing +24% vs. +9%. General Motors delivered better-than-expected adjusted earnings per share in third-quarter 2017. Revenues also surpassed expectations.
In the United States, in October, the automaker reported 252,813 deliveries. During the month, pickup deliveries rose 9% year over year and crossover deliveries rose 12% year over year. The company aims to focus more on the development of electric vehicles and plans to roll out 20 electric or hydrogen fuel cell vehicles by 2023.
It is also emphasizing to strengthen its brands, increasing retail sales and maintaining operating discipline. However, frequent vehicle recalls, high inventory level of passenger cars and currency fluctuations are few concerns the company has been facing.
Enterprise Products Partners' shares have gained +1.4 over the last year, even as the Zacks Oil Production Pipeline MLP industry declined by -7.7%. Enterprise Products has an extensive network of pipeline that spreads over almost 50,000 miles. The pipeline is connected to every major U.S. shale play and provides services to producers and users of commodities by transporting natural gas liquid (NGL), natural gas, crude oil and refined products.
The partnership has raised its cash distribution for 52nd successive quarters, reflecting stable fee-based cash flow from diversified midstream assets. It is expected that Enterprise Products Partners will maintain the trend as the partnership has a backlog of almost $9 billion fee-based growth projects.
However, the partnership’s escalating debt since 2012 reflects its weak balance sheet. The Zacks analyst is concerned about Enterprise Products’ rising operating costs.
Other noteworthy reports we are featuring today Berkshire Hathaway (BRK.B - Free Report) and PetroChina .
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: CVS Health, General Motors, Enterprise Products, Berkshire Hathaway and PetroChina
For Immediate Release
Chicago, IL – November 8, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include CVS Health (CVS - Free Report) , General Motors (GM - Free Report) , Enterprise Products (EPD - Free Report) , Berkshire Hathaway (BRK.B - Free Report) and PetroChina .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for CVS, GM and Enterprise Products
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including CVS Health, General Motors and Enterprise Products. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
CVS Health’s shares have outperformed the Zacks Drug Stores industry over the last six months losing -17.6% vs. a decline of -21.1%. CVS Health exited the third quarter on a solid note with both earnings and revenues remaining ahead of the expectations.
Slower revenue performance on poor Retail/LTC numbers as well as margin debacle resulted in such a dull bottom line performance by the company in the quarter. Nonetheless, year-over-year growth in the top line was due to strong Pharmacy Services segment that benefited from the upside in the Specialty Pharmacy.
The Zacks analyst is encouraged to note that, despite a soft bottom-line scenario, the company reiterated its earnings outlook for 2017 indicating chances of recovery ahead. The company’s on-going strong 2018 PBM selling season is another upside. Moreover, the Omnicare and Target Pharmacy buyouts are gradually driving enterprise value at CVS Health.
(You can read the full research report on CVS Health here >>>).
Shares of General Motors have outperformed the Zacks Domestic Automotive industry over the last six months, increasing +24% vs. +9%. General Motors delivered better-than-expected adjusted earnings per share in third-quarter 2017. Revenues also surpassed expectations.
In the United States, in October, the automaker reported 252,813 deliveries. During the month, pickup deliveries rose 9% year over year and crossover deliveries rose 12% year over year. The company aims to focus more on the development of electric vehicles and plans to roll out 20 electric or hydrogen fuel cell vehicles by 2023.
It is also emphasizing to strengthen its brands, increasing retail sales and maintaining operating discipline. However, frequent vehicle recalls, high inventory level of passenger cars and currency fluctuations are few concerns the company has been facing.
(You can read the full research report on General Motors here >>>).
Enterprise Products Partners' shares have gained +1.4 over the last year, even as the Zacks Oil Production Pipeline MLP industry declined by -7.7%. Enterprise Products has an extensive network of pipeline that spreads over almost 50,000 miles. The pipeline is connected to every major U.S. shale play and provides services to producers and users of commodities by transporting natural gas liquid (NGL), natural gas, crude oil and refined products.
The partnership has raised its cash distribution for 52nd successive quarters, reflecting stable fee-based cash flow from diversified midstream assets. It is expected that Enterprise Products Partners will maintain the trend as the partnership has a backlog of almost $9 billion fee-based growth projects.
However, the partnership’s escalating debt since 2012 reflects its weak balance sheet. The Zacks analyst is concerned about Enterprise Products’ rising operating costs.
(You can read the full research report on Enterprise Products Partners here >>>).
Other noteworthy reports we are featuring today Berkshire Hathaway (BRK.B - Free Report) and PetroChina .
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performancefor information about the performance numbers displayed in this press release.